Restricted accessResearch articleFirst published online 2015-01
Thrombopoietin Treatment of One Graft in a Double Cord Blood Transplant Provides Early Platelet Recovery While Contributing to Long-Term Engraftment in NSG Mice
Human cord blood (CB) hematopoietic stem cell (HSC) transplants demonstrate delayed early neutrophil and platelet recovery and delayed longer term immune reconstitution compared to bone marrow and mobilized peripheral blood transplants. Despite advances in enhancing early neutrophil engraftment, platelet recovery after CB transplantation is not significantly altered when compared to contemporaneous controls. Recent studies have identified a platelet-biased murine HSC subset, maintained by thrombopoietin (TPO), which has enhanced capacity for short- and long-term platelet reconstitution, can self-renew, and can give rise to myeloid- and lymphoid-biased HSCs. In previous studies, we have shown that transplantation of human CB CD34+ cells precultured in TPO as a single graft accelerates early platelet recovery as well as yielding long-term repopulation in immune-deficient mice. In this study, using a double CB murine transplant model, we investigated whether TPO cultured human CB CD34+ cells have a competitive advantage or disadvantage over untreated human CB CD34+ cells in terms of (1) short-term and longer term platelet recovery and (2) longer term hematological recovery. Our studies demonstrate that the TPO treated graft shows accelerated early platelet recovery without impairing the platelet engraftment of untreated CD34+ cells. Notably, this was followed by a dominant contribution to platelet production through the untreated CD34+ cell graft over the intermediate to longer term. Furthermore, although the contribution of the TPO treated graft to long-term hematological engraftment was reduced, the TPO treated and untreated grafts both contributed significantly to long-term chimerism in vivo.
Get full access to this article
View all access options for this article.
References
1.
BallenKK, GluckmanE and BroxmeyerHE. (2013). Umbilical cord blood transplantation: the first 25 years and beyond. Blood, 122:491–498.
2.
WattSM. (2014). Umbilical Cord Blood Banking. Reference Module in Biomedical Sciences. CaplanMJ, editor in chief. Elsevier Press, Kidligton, United Kingdom, Article 04238.
3.
BallenKK, KorethJ, ChenYB, DeyBR and SpitzerTR. (2012). Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood, 119:1972–1980.
4.
FuchsE, O'DonnellPV and BrunsteinCG. (2013). Alternative transplant donor sources: is there any consensus?. Curr Opin Oncol, 25:173–179.
5.
HidalgoA and FrenettePS. (2005). Enforced fucosylation of neonatal CD34+ cells generates selectin ligands that enhance the initial interactions with microvessels but not homing to bone marrow. Blood, 105:567–575.
6.
XiaL, McDanielJM, YagoT, DoedenA and McEverRP. (2004). Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood, 104:3091–3096.
7.
HoggattJ, MohammadKS, SinghP and PelusLM. (2013). Prostaglandin E2 enhances long-term repopulation but does not permanently alter inherent stem cell competitiveness. Blood, 122:2997–3000.
8.
PageKM, MendizabalA, Betz-StableinB, WeasS, ShoularsK, GentryT, PrasadVK, SunJ, CarterS, BalberAE and KurtzbergJ. (2014). Optimizing donor selection for public cord blood banking: influence of maternal, infant, and collection characteristics on cord blood unit quality. Transfusion, 54:340–352.
9.
PageKM, ZhangL, MendizabalA, WeaseS, CarterS, ShoularsK, GentrT, BalberAE and KurtzbergJ. (2012). The cord blood Apgar: a novel scoring system to optimize selection of banked cord blood grafts for transplantation (CME). Transfusion, 52:272–283.
10.
PageKM, ZhangL, MendizabalA, WeaseS, CarterS, GentryT, BalberAE and KurtzbergJ. (2011). Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants. Biol Blood Marrow Transplant, 17:1362–1374.
11.
BarkerJN, ScaradavouA and StevensCE. (2010). Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood, 115:1843–1849.
12.
TerakuraS, AzumaE, MurataM, KumamotoT, HirayamaM, AtsutaY, KoderaY, YazakiM, NaoeT and KatoK. (2007). Hematopoietic engraftment in recipients of unrelated donor umbilical cord blood is affected by the CD34+ and CD8+ cell doses. Biol Blood Marrow Transplant, 13:822–830.
13.
LemarieC, EsterniB, CalmelsB, DazeyB, LapierreV, LecchiL, MeyerA, ReaD, ThuretI, et al. (2007). CD34+ progenitors are reproducibly recovered in thawed umbilical grafts, and positively influence haematopoietic reconstitution after transplantation. Bone Marrow Transplant, 39:453–460.
14.
WagnerJE, BarkerJN, DeForTE, BakerKS, BlazarBR, EideC, GoldmanA, KerseyJ, KrivitW, et al. (2002). Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood, 100:1611–1618.
15.
MigliaccioAR, AdamsonJW, StevensCE, DobrilaN, CarrierCM and RubinsteinP. (2000). Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. Blood, 96:2717–2722.
16.
ScaradavouA, SmithKM, HawkeR, SchaibleA, AbboudM, KernanNA, YoungJW and BarkerJN. (2010). Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation. Biol Blood Marrow Transplant, 16:500–508.
17.
AveryS, ShiW, LubinM, GonzalesAM, HellerG, Castro-MalaspinaH, GiraltS, KernanNA, ScaradavouA and BarkerJN. (2011). Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood, 117:3277–3285.
18.
ScaradavouA, BrunsteinCG, EapenM, Le-RademacherJ, BarkerJN, ChaoN, CutlerC, DelaneyC, KanF, et al. (2013). Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood, 121:752–758.
19.
OranB. (2012). Can double-cord transplants provide a more potent graft-vs-leukemia effect?. Best Pract Res Clin Haematol, 25:479–482.
20.
BrunsteinCG, GutmanJA, WeisdorfDJ, WoolfreyAE, DeForTE, GooleyTA, VernerisMR, AppelbaumFR, WagnerJE and DelaneyC. (2010). Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood, 116:4693–4699.
21.
VernerisMR, BrunsteinCG, BarkerJ, MacMillanML, DeForT, McKennaDH, BurkeMJ, BlazarBR, MillerJS and McGlavePB. (2009). Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood, 114:4293–4299.
22.
RamirezP, WagnerJ, DeForT, EideC, MillerJ, WeisdorfD and BrunsteinC. (2013). CXCR4 expression in CD34+ cells and unit predominance after double umbilical cord blood transplantation. Leukemia, 27:1181–1183.
23.
DahlbergA, DelaneyC and BernsteinID. (2011). Ex vivo expansion of human hematopoietic stem and progenitor cells. Blood, 117:6083–6090.
24.
KellyS, SolaC, De LimaM and ShpallE. (2009). Ex vivo expansion of cord blood. Bone Marrow Transplant, 44:673–681.
25.
de LimaM, McNieceI, RobinsonSN, MunsellM, EapenM, HorowitzM, AlousiA, SalibaR, McMannisJD and KaurI. (2012). Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med, 367:2305–2315.
26.
DelaneyC, HeimfeldS, Brashem-SteinC, VoorhiesH, MangerRL and BernsteinID. (2010). Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med, 16:232–236.
FaragSS, SrivastavS, Messina-GrahamS, SchwartzJ, RobertsonMJ, AbonourR, CornettaK, WoodL, SecrestA, et al. (2013). In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev, 22:1007–1015.
30.
ChristophersonKW2nd, HangocG, MantelCR and BroxmeyerHE. (2004). Modulation of hematopoietic stem cell homing and engraftment by CD26. Science, 305:1000–1003.
DanbyR and RochaV. (2014). Improving engraftment and immune reconstitution in umbilical cord blood transplantation. Front Immunol, 5:68–72.
33.
GuttridgeMG, SohTG, BelfieldH, SiddersC and WattSM. (2014). Storage time affects umbilical cord blood viability. Transfusion, 54:1278–1285.
34.
de SauvageFJ, Carver-MooreK, LuohSM, RyanA, DowdM, EatonDL, MooreMW. (1996). Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med, 183:651–656.
35.
YoshiharaH, AriaF, HosokawaK, HagiwaraT, TakuboK, NakamuraY, GomeiY, IwasakiH, MatsuokaS, et al. (2007). Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell, 1:685–697.
36.
QianH, Buza-VidasN, HylandCD, JensenCT, AntonchukJ, ManssonR, ThorenLA, EkblomM, AlexanderWS and JacobsenSEW. (2007). Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell, 1:671–684.
37.
KuterDJ. (2013). The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol, 98:10–23.
38.
YagiM, RitchieKA, SitnickaE, StoreyC, RothGJ and BartelmezS. (1999). Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin. Proc Natl Acad Sci USA, 96:8126–8131.
39.
NgAP, KauppiM, MetcalfD, HylandCD, JosefssonEC, LeboisM, ZhangJG, BaldwinTM, Di RagoL, HiltonDJ and AlexanderWS. (2014). Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. Proc Natl Acad Sci USA, 111:5884–5889.
40.
NgAP, KauppiM, MetcalfD, Di RagoL, HylandCD and AlexanderWS. (2012). Characterization of thrombopoietin (TPO)-responsive progenitor cells in adult mouse bone marrow with in vivo megakaryocyte and erythroid potential. Proc Natl Acad Sci USA, 109:2364–2369.
41.
Sanjuan-PlaA, MacaulayIC, JensenCT, WollPS, luisTC, MeadA, MooreS, CarellaC, MatsuokaS, et al. (2013). Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature, 502:232–236.
42.
MattiaG, MilazzoL, VulcanoF, PascuccioM, MacioceG, HassanHJ and GiampaoloA. (2008). Long–term platelet production assessed in NOD/SCID mice injected with cord blood CD34+ cells, thrombopoietin–amplified in clinical grade serum–free culture. Exp Hematol, 36:244–252.
43.
SchipperLF, BrandA, ReniersN, MeliefCJ, WillemzeR and FibbeWE. (2003). Differential maturation of megakaryocyte progenitor cells from cord blood and mobilized peripheral blood. Exp Hematol, 31:324–330.
44.
van HensbergenY, SchipperLF, BrandA, SlotMC, WellingM, NautaAJ and FibbeWE. (2006). Ex vivo culture of human CD34+ cord blood cells with thrombopoietin (TPO) accelerates platelet engraftment in a NOD/SCID mouse model. Exp Hematol, 34:943–950.
45.
BolwellB, PohlmanB, SobecksR, AndresenS, BrownS, RybickiL, WentlingV and KalaycioM. (2004). Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant, 33:419–423.
46.
SutherlandDR, AndersonL, KeeneyM, NayarR and Chin-YeeI. (1996). The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother, 5:213–226.
47.
SchipperLF, van HensbergenY, FibbeWE and BrandA. (2007). A sensitive quantitative single-platform flow cytometry protocol to measure human platelets in mouse peripheral blood. Transfusion, 47:2305–2314.
48.
van HensbergenY, MulderA, CornelissenJJ and BrandA. (2013). Validation of human monoclonal HLA Class I antibodies to evaluate the kinetics of donor chimerism in different cell subsets after double-cord blood transplantation in the NOD/SCID model. Transfusion, 53:104–114.
49.
MulderA, KardolMJ, ArnJS, EijsinkC, FrankeME, SchreuderGM, HaasnootGW, DoxiadisII, SachsDH and SmithDM. (2010). Human monoclonal HLA antibodies reveal interspecies crossreactive swine MHC class I epitopes relevant for xenotransplantation. Mol Immunol, 47:809–815.
50.
SomersJA, BrandA, van HensbergenY, MulderA, OudshoornM, SintnicolaasK, GratamaJ-W, FalkenburgJ, BraakmanE and CornelissenJJ. (2013). Double umbilical cord blood transplantation: A study of early engraftment kinetics in leukocyte subsets using HLA-specific monoclonal antibodies. Biol Blood Marrow Transplant, 19:266–273.
51.
SchipperLF, BrandA, FibbeWE and Van HensbergenY. (2012). Functional characterization of TPO-expanded CD34+ cord blood cells identifies CD34− CD61− cells as platelet-producing cells early after transplantation in NOD/SCID mice and rCD34+ cells as CAFC colony-forming cells. Stem Cells, 30:988–996.
52.
BreemsD, BloklandE, NebenS and PloemacherR. (1994). Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia, 8:1095
53.
WalletHL, SobhM, MorissetS, RobinM, FegueuxN, FürstS, MohtyM, DeconinckE, FouillardL and BordigoniP. (2014). Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry. Exp Hematol, 42:161–162.
54.
BrunoB, GooleyT, SullivanKM, DavisC, BensingerWI, StorbR and NashRA. (2001). Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 7:154–162.
55.
GekasC and GrafT. (2014). CD41 expression marks myeloid-biased adult hematopoietic stem cells and increases with age. J Exp Med, 211:217–231.
56.
ShinJY, HuW, NaramuraM and ParkCY. (2013). High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias. Blood, 121:4463–4472.
57.
LaurentiE, DoulatovS, ZandS, PlumbI, ChenJ, AprilC, FanJB and DickJE. (2013). The transcriptional architecture of early human hematopoiesis identifies multilevel control of lymphoid commitment. Nat Immunol, 14:756–763.
58.
GörgensA, RadtkeS, MöllmannM, CrossM, DürigJ, HornPA and GiebelB. (2013). Revision of the human hematopoietic tree: granulocyte subtypes derive from distinct hematopoietic lineages. Cell Rep, 3:1539–1552.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
